N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide manufacturers
- Safotibant
-
- $88.00
-
2026-06-03
- CAS:633698-99-4
- Purity: 99.62%
- Supply Ability: 10g
|
| | N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide Basic information |
| | N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide Chemical Properties |
| Boiling point | 680.4±65.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | pka | 9.92±0.40(Predicted) |
| | N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide Usage And Synthesis |
| Uses | Safotibant is a reagent with pharmocological activity to inhibited retinal inflammation and oxidative stress in rat with Zanosar induced diabetes | | in vivo | Safotibant (10 mg/kg, s.c., 3 times a day for 8 days) exhibits analgesic property against bone cancer-induced pain in osteolytic sarcoma xenograft C3H/HeJ mice model, without affecting disease progression[1].
Safotibant (one eye drop application, twice a day for 7 days) inhibits expressions of inflammatory mediators B1R, iNOS, IL-1β, COX-2, VEGF-R2 and HIF-1α, reverses diabetes-induced retinal inflammation and oxidative stress in streptozotocin (STZ)-diabetic Wistar rats model[2]. | Animal Model: | Osteolytic sarcoma xenograft C3H/HeJ mice model[1] | | Dosage: | 10 mg/kg | | Administration: | s.c., 3 times a day for 8 days | | Result: | Decreased numbers of flinching and time spent on spontaneous guarding. |
| Animal Model: | Streptozotocin (STZ)-diabetic Wistar rats model[2] | | Dosage: | One eye drop | | Administration: | On eyes application, twice a day for 7 days | | Result: | Reversed retinal vascular hyperpermeability, decreased levels of retinal leukostasis and superoxide anion in 3 retinal nuclear layers. |
|
| | N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide Preparation Products And Raw materials |
|